Información del artículo
El Texto completo está disponible en PDF
Biblografía
[2.]
C. Wang, L.M. Crapo.
The epidemiology of thyroid disease and implications for screening.
Endocrinol Metab Clin North Am, 26 (1997), pp. 189-218
[3.]
A. Pilo, G. Iervasi, F. Vitek, M. Ferdeghini, F. Cazzuola, R. Bianchi.
Thyroid and peripheral production of 3,5,3’-triiodothyronine in humans by multicompartmental analysis.
Am J Physiol, 1990 (1990), pp. E715-E726
[4.]
M. Saberi, R.D. Utiger.
Serum thyroid homrone and thyrotropin concentrations during thyroxine and triiodothyronine therapy.
J Clin Endocrinol Metab, 39 (1974), pp. 923-927
[5.]
S. Taylor, M. Kapur, R. Adie.
Combined thyroxine and triiodothyronine for thyroid replacement therapy.
Br Med J, 1 (1970), pp. 270-271
[6.]
R.N. Smith, S.A. Taylor, J.C. Massey.
Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism.
Br Med J, 4 (1970), pp. 145-148
[7.]
M.I. Surks, A.R. Schadlow, J.H. Oppenheimer.
A new radioimmunoassay for plasma L-triiodothyronine: measurement in thyroid disease and in patients maintained on hormonal replacement.
J Clin Invest, 51 (1972), pp. 3104-3113
[8.]
R. Bunevicius, G. Kazanavicius, R. Zalinkevicius, A. Prange Jr.
Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism.
N Engl J Med, 340 (1999), pp. 424-429
[9.]
H.F. Escobar-Morreale, M.J. Obregón, R. Calvo, F. Escobar del Rey, G. Morreale de Escobar.
Continuous infusion of different doses of T4 or T3 in thyroidectomized rats: circulating and tissue levels of T4 and T3.
Program of the 67ht Annual Meeting of the American Thyroid Association, Tampa, (1993), pp. T49
[10.]
H.F. Escobar-Morreale, M.J. Obregón, F. Escobar del Rey, G. Morreale de Escobar.
Replacement therapy for hypothyroidism with thyroxine aloe does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats.
J Clin Invest, 96 (1995), pp. 2828-2838
[11.]
H.F. Escobar-Morreale, F. Escobar del Rey, M.J. Obregón, Escobar. Morreale de.
Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat.
Endocrinology, 137 (1996), pp. 2490-2502
[12.]
L.H. Fish, H.L. Schwartz, J. Cavanaugh, M.W. Steffes, J.P. Bantle, J.H. Oppenheimer.
Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in human.
N Engl J Med, 316 (1987), pp. 764-770
[13.]
H.F. Escobar-Morreale, M.J. Obregon, F. Escobar del Rey, G. Morreale de Escobar.
Tissue-specific patterns of changes in 3,5,3’-triiodo-L-thyronine concentrations in thyroidectomized rats infused with increasing dose of the hormone. Which are the regulatory mechanisms?.
Biochimie, 81 (1999), pp. 453-462
[14.]
H.F. Escobar-Morreale, M.J. Obregón, A. Hernández, F. Escobar del Rey, G. Morreale de Escobar.
Regulation of iodothyronine deiodinase activity as studied in thyroidectomized rats infused with thyroxine of triiodothyronine.
Endocrinology, 138 (1997), pp. 2559-2568
[15.]
S.M. Gow, G. Caldwell, A.D. Toft, J. Seth, A.J. Hussey, V.M. Sweeting, et al.
Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement.
J Clin Endocrinol Metab, 64 (1987), pp. 364-370
[16.]
E. Brucket, P. Giral, R. Chadarevian, G. Turpin.
Low free-thyroxine levels are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patients.
J Cardiovasc Risk, 6 (1999), pp. 327-331
[17.]
W.M. Wiersinga.
Hypothyroidism.
Thyroid disease manager,
[18.]
B. Biodi, S. Fazio, E.A. Palmieri, C. Carella, N. Panza, A. Cittadini, et al.
Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism.
J Clin Endocrinol Metab, 84 (1999), pp. 2064-2067
[19.]
M. Bettendorf, K.G. Schmidt, J. Grulich-Henn, H.E. Ulmer, U.E. Heinrich.
Triodothyronine treatment in children after cardiac surgery: a doubleblind, randomised, placebo-controlled study.
Lancet, 356 (2000), pp. 529-534
[20.]
D.S. Cooper, R. Halpern, L.C. Wood, A.A. Levin, E.C. Ridgway.
L-thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial.
Ann Intern Med, 101 (1984), pp. 18-24
[21.]
R. Jaeschke, G. Guyatt, H. Gerstein, C. Patterson, W. Molloy, D. Cook, et al.
Does treatment with L-thyroxine influence health status in middleaged and older adults with subclinical hypothyroidism?.
J Gen Intern Med, 11 (1996), pp. 744-749
[22.]
E. Nyström, K. Caidahl, G. Fager, C. Wikkelso, P.A. Lundberg, G. Lidstedt.
A double-blind cross-over 12-month study of L-thyroxine treatment of women with ’subclinical’ hypothyroidism.
Clin Endocrinol (Oxf), 29 (1988), pp. 63-75
[23.]
R. Arem, D. Escalante.
Subclinical hypothyroidism: epimiology, diagnosis, and significance.
Adv Intern Med, 41 (1996), pp. 213-250
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición